Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas
Soft tissue sarcoma (STS) constitutes a rare group of heterogeneous malignancies. Effective treatment options for most subtypes of STS are still limited. As a result, especially in metastatic disease, prognosis is still dismal. The ligands for the activating immunoreceptor NKG2D (NKG2DL) are commonl...
Main Authors: | Ilona Hagelstein, Martina S. Lutz, Moritz Schmidt, Jonas S. Heitmann, Elke Malenke, Yanjun Zhou, Kim L. Clar, Hans-Georg Kopp, Gundram Jung, Helmut R. Salih, Melanie Märklin, Clemens Hinterleitner |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.653081/full |
Similar Items
-
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
by: Melanie Märklin, et al.
Published: (2019-05-01) -
CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
by: Joseph Kauer, et al.
Published: (2021-09-01) -
An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia
by: Fabian Riegg, et al.
Published: (2021-04-01) -
Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells
by: Stefanie Maurer, et al.
Published: (2018-02-01) -
DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis
by: Anna Chashchina, et al.
Published: (2021-09-01)